A placebo‐controlled dose response study of the reactogenicity and immunogenicity of a live cold‐recombinant influenza B virus vaccine in healthy volunteers | Zendy

Ganzinger U. | Zendy; Bachmayer H. | Zendy; Liehl E. | Zendy; Martindale J. J. | Zendy; Hamilton F. | Zendy; Kuwert E. K. | Zendy

Premium

A placebo‐controlled dose response study of the reactogenicity and immunogenicity of a live cold‐recombinant influenza B virus vaccine in healthy volunteers

Author(s) -

Ganzinger U.,

Bachmayer H.,

Liehl E.,

Martindale J. J.,

Hamilton F.,

Kuwert E. K.

Publication year - 1988

Publication title -

journal of medical virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.782

H-Index - 121

eISSN - 1096-9071

pISSN - 0146-6615

DOI - 10.1002/jmv.1890250211

Subject(s) - reactogenicity , immunogenicity , virology , virus , recombinant dna , influenza vaccine , medicine , live attenuated influenza vaccine , biology , immunology , antibody , gene , biochemistry

A live cold‐recombinant influenza B virus vaccine (RB77) was given intranasally in a placebo‐controlled, double blind study to volunteers in dosages of 10 7.9 EID 50 /ml, 10 7.25 EID 50 /ml, 10 5.7 EID 50 /ml. The tolerability, safety, and immunogenicity of the vaccine were investigated. No revertant virus was found in nasal swabs taken after immunisation. Local reactions were mild and showed a significant increase over the placebo only in the highest dose group. Systemic reactions were not different from the placebo. A significant increase in haemagglutinin inhibition titre was found in the highest dose group against the immunising strain (RB77) and the two wild strains B/TEC and B/Sing.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research